Evofem Bioscienc Stock Price, News & Analysis

Evofem Biosciences announces a strategic partnership with VitaCare Prescription Services to enhance patient access to Phexxi, a contraceptive product. This agreement aims to streamline the prescription process, leading to an increase in filled prescriptions. VitaCare will provide 'white glove' support to patients, improving follow-up and facilitating communications between healthcare providers and insurers. Key services include personalized benefits guidance, prior authorization support, and refill reminders. This collaboration is part of Evofem's broader strategy to efficiently support its growing patient base.

Evofem Biosciences (Nasdaq: EVFM) will present data from the Phase 3 AMPOWER Clinical Trial at the ACOG annual meeting on May 7, 2022. The poster will characterize women who experienced urinary tract infections during the trial. Katherine Atkinson, CCO of Evofem, emphasized the company's commitment to improving women's sexual and reproductive health. Additionally, Evofem will host a product theatre discussing its FDA-approved, hormone-free contraceptive gel, Phexxi®, on May 6, 2022. This innovative product aims to fill unmet needs in women's health.

Evofem Biosciences (Nasdaq: EVFM) will hold a conference call on May 4, 2022, at 4:30 p.m. ET to discuss its first-quarter 2022 financial results and business highlights. Participants can join the call via phone or webcast. For the phone dial-in, use (877) 407-0890 (U.S. toll-free) or (201) 389-0918. The company is known for its innovative products in women's sexual and reproductive health, including the FDA-approved product, Phexxi®. To learn more, visit phexxi.com.

Evofem Biosciences announced that 88.7% of women using Phexxi reported improvement or maintenance of sexual satisfaction in the Phase 3 AMPOWER clinical trial. The study, published in the Journal of Sexual Medicine, involved 1,330 sexually active women aged 18-35. The data highlighted that 93% of participants would recommend Phexxi, a non-hormonal contraceptive gel approved by the FDA to prevent pregnancy. Insights from this trial may enhance understanding of women's sexual health.

Evofem Biosciences (Nasdaq: EVFM) has appointed Karina Fedasz as its new Head of Business Development, effective immediately. Her role focuses on expanding markets for Phexxi, Evofem's first-in-class hormone-free contraceptive. Fedasz brings extensive experience in deal-making and partnerships, having previously executed significant global deals. The company aims to enhance access to Phexxi both domestically and internationally. Evofem is set to report its first-quarter results on May 4, 2022.

Evofem Biosciences, Inc. (Nasdaq: EVFM) has received approval from the Nasdaq Hearings Panel to continue its listing while awaiting shareholder vote on a proposed reverse stock split. This vote is scheduled for May 4, 2022. The proposed split ratio ranges from 1-for-5 to 1-for-15 shares. This action aims to ensure compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as the company received a deficiency letter in August 2021. The company must regain compliance by May 20, 2022, or risk delisting.

Evofem Biosciences (Nasdaq: EVFM) announced significant findings from the Phase 2B/3 AMPREVENCE clinical trial, showcasing a 50% reduction in chlamydia and a 78% reduction in gonorrhea among women using EVO100 (investigational name for Phexxi). The trial involved 860 females aged 18-45 with prior infections. Additionally, patient satisfaction data were collected, contributing to the ongoing EVOGUARD Phase 3 trial, with topline results expected in late 2022. These findings aim to enhance access for EVO100 if approved.

Evofem Biosciences has completed enrollment in the EVOGUARD Phase 3 clinical trial for EVO100 (Phexxi) targeting prevention of chlamydia and gonorrhea among women. The trial exceeded its initial enrollment goal, reaching 1,903 participants, allowing for robust data collection. Top-line results are anticipated in late 2022. The FDA's QIDP designation for EVO100 may provide five additional years of exclusivity, and there is a noted need for new preventive options in light of rising infection rates. The complete trial outcome could significantly influence women's sexual health.

Evofem Biosciences, Inc. (Nasdaq: EVFM) reported strong growth for Q4 2021, with net product sales rising 109% to $3.6 million, largely due to a 73% increase in Phexxi units shipped. The company reduced its cash burn rate to $16.8 million from $32.0 million in Q3. Evofem also completed enrollment in its Phase 3 clinical trial for Phexxi, targeting new indications against chlamydia and gonorrhea, expecting to submit data to the FDA in early 2023. The total operating expenses for Q4 were $41.0 million, down from $45.1 million in Q3.